ANP32E expression in pancreatic cancer is associated with impaired gemcitabine efficacy and poor patient prognosis

ANP32E expression in pancreatic cancer is associated with impaired gemcitabine efficacy and poor patient prognosis

Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive and fatal malignancy, although gemcitabine is administered as a single or combined therapeutic agent. Our previous study demonstrated that ANP32E overexpression promoted PDAC cell proliferation. However, whether it affects treat...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaohong Liu, Yelin Zhao, Li Zhang, Junting Wang, Liaoxin Luo, Shihui Zhang, Qin Zhu, Yuchen Shi, Chenyu Yuan, Qifeng Xiao, Mengran Xiong, Yuanyuan Duan, Hebing Chen, Hongjuan Yao, Lin Cai, Jianwei Zhang, Guangxi Li, Liang Li
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:Molecular and Cellular Probes
Subjects:
Pancreatic ductal adenocarcinoma
ANP32E
Prognosis biomarker
Gemcitabine resistance
Online Access:http://www.sciencedirect.com/science/article/pii/S0890850825000234
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items